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Obesity is a serious issue that no longer remains a simple problem of aesthetics but
signifies a crisis of health. Evidence shows strong connections between mortality
from chronic diseases and obesity1,2 that has led to classifying obesity as a treata-
ble disease. One such treatment, appetite-suppressants, known as anorexigens, has
been developed and prescribed to patients for many years. However, some of these
medications have had a history of harmful side effects with unacceptable mor-
tality and morbidities.3,4
In Europe during 1960s, the after-effects of aminorex has been grossly tied with
pulmonary arterial hypertension (PAH). Also, in 1980s there were reports of pri-
mary pulmonary hypertension (PPH) and valvulopathy in patients who were treat-
ed with fenfluramine.5-9 As a compound, phentermine and fenfluramine have
similar structures (Fig. 1), and both compounds have often been prescribed con-
currently as an appetite-suppressant when in the 1980s their concurrent usage was
reported to have a synergistic effect.10 In time, fenfluramine-phentermine (Fen-
Phen) concurrent medication was proven to play a certain role in the development
of PPH and valvular heart diseases. However, there has been no reported study
that made a case against phentermine single medication to date. 
In this case, we report that phentermine single medication causes the same
effects of increased prevalence of PAH as those of single fenfluramine or Fen-
Phen concurrent medication. 
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Weight-control drugs (known as anorexigens) such as fenfluramine have been
linked with pulmonary hypertension in previous reports. In our case, a 29 year old
woman was admitted for shortness of breath and was diagnosed with pulmonary
hypertension. Three months ago, she had been taking phentermine for five weeks.
Other factors that might have contributed to the development of pulmonary
hypertension were excluded. With treatment, her symptoms improved. This is the
first case that can suggest a possible connection between phenermine single
medication with pulmonary hypertension. Phentermine has been considered a
relatively safe drug to treat obesity, and further investigation is needed to decide
the safety and dosage of phentermine.
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Three month before hospitalization, a 29 year-old woman
sought medical help for obesity. She was otherwise heal-
thy and did not smoke cigarettes. There was no family
history of pulmonary hypertension. She had not been pre-
gnant and did not take any other medications including
oral contraceptives and herbal medications at the time of
symptom onset. She weighted 73 kg and was 1.60 m (65
in.) tall. Her body-mass index (the weight in kilograms
divided by the square of the height in meters) was 28. Oral
medication therapy with phentermine HCl (adipex®) at a
dose of 37.5 mg taken every morning was prescribed. The
medication continued for 35 days, during which the patient
lost 13 kg. After two months since the start of the prescrip-
tion, the patient began to feel tachycardia and she was
admitted for shortness of breath. Laboratory investigation
did not show abnormal findings. Chest radiographs show-
ed mild prominence of the right ventricular outflow tract.
Right ventricular hypertrophy was shown in electrocardio-
graphy (Fig. 2) while echocardiography showed moderate
pulmonary hypertension (right ventricular pressure: 63
mmHg) with tricuspid regurgitation and D-shaped left
ventricle (LV) (Fig. 3). There was no pericardial effusion.
Cardiac catheterization showed moderate pulmonary hyper-
tension and elevated pulmonary vascular resistance. The
right ventricular pressure was 70/29 mmHg; the pulmonary-
artery pressure was 69/26 mmHg, with a mean of 42 mmHg
while resting; the pulmonary-capillary wedge pressure was
7 to 11 mmHg. A heart MRI showed no visible intracar-
diac shunt or pulmonary thromboembolism. Other studies
were performed to rule out various causes of pulmonary
hypertension. Liver-function studies showed a mild eleva-
tion of alanine aminotransferase. Abdominal ultrasonogra-
phy revealed no liver abnormalities. Tests for anti-centro-
mere antibodies and anti-HIV Ag were negative.
Bosentan 125 mg was prescribed with diuretics. Radical
anticoagulation therapy was administered. The patient was
discharged after three days and followed-up with subjec-
tive symptom improvement.
Phentermine is an anorexigen which had been approved
for short-term use as a treatment of obesity by US FDA in
1959, and has been used since. Phentermine stimulates the
secretion of noradrenalin in the central nervous system,
and suppresses appetite by regulatingthe β-adrenergic recep-
tors.11 When phentermine and fenfluramine combination
treatment was reported to have a synergistic effect on the
dopamine and serotonin release in the rat brain,10 Fen-Phen
treatment became the mainstay of anorexin treatment of
the 1980s. However, this combination treatment was sug-
gested to have strong ties with PAH and valvular heart dis-
ease while fenfluramine single medication was also report-
ed with the same side-effects that in November 1997 the
US FDA banned the prescription of fenfluramine altoge-
ther. However, to date, the FDA still allows the short term
use of phentermine. In the 2000 report by Rich, et al.,12 con-
cerning the surveillance data on anorexigens and pulmo-
nary hypertension, the only drug that had a meaningfully
causal relationship with PPH amongst antidepressants,
CASE REPORT
Fig. 1. Chemical structure of anorexigens. Note structural similarity of phenter-
mine and fenfluramine. 
Fig. 2. Chest X-ray and ECG. Chest radiographs showed mild prominence of the
right ventricular outflow tract. Sign of right ventricular hypertrophy was shown
in electrocardiography.
Fig. 3. Sign of RV pressure overload on echocardiography. Echocardiography
showed tricuspid regurgitation and D-shaped LV. RV systolic pressure
estimated 63 mmHg. RV, right ventricle. LV, left ventricle.
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anorexigens, and amphetamines was fenfluramines. So far,
there exists very few cases and no controlled studies sug-
gesting a connection between PPH  and the use of other
appetite suppressants such as phentermine.13,14
A concrete evaluation on the safety of phentermine
single treatment is still unavailable and there has not been
a reported case since 2000.15 However, there had been stud-
ies in the 1990s that raised suspicions that phentermine
might have similar correlations with PAH as with fenflura-
mine. In one study, fenfluramine-like medications were
suggested to increase the risk of PPH via affecting seroto-
nin [5-Hydroxytryptamine (5-HT)] transporters.16
Rothman, et al.17 reported that some medications known
to increase the risk of PPH (e.g., aminorex, fenfluramine,
and chlorphentermine) are 5-HT transporter substrates.
The role of 5-HT transporters in the development of PAH
has been well-evaluated. 5-HT transporter substrates are
translocated into pulmonary cells where, depending on the
degree of drug retention, their intrinsic toxicity, and indivi-
dual susceptibility, PPH may develop as a response to con-
centrations of these drugs or metabolites. According to
Rothman, the duration and dosage of the drug also had a
direct relationship with the increase in the relative risk of
PAH after treatment. If this evidence can be supported by a
considerable number of clinical cases, the FDA must
amend its decision to allow the usage of a drug that is now
in use without safe guidelines. The current Physician’s
Desk Reference (PDR) guideline allows phentermine for a
duration of 3-6 weeks; however, in our case, the patient had
developed PAH with 5 weeks of medication. 
In summary, we propose that the usage of phentermine
might be associated with PAH by presenting the above
case. Although phentermine has been considered a safe
drug for obesity, further study should be underway to esta-
blish safety and dosage of phentermine.
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